hematologic malignancy

Type: Keyphrase
Name: hematologic malignancy
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Factors in Late Hospice Admission for Cancer Identified

Share this article:Late admission more likely for younger patients, married men, hematologic malignancies.For patients with cancer , factors associated with late admission to hospice have been identified, according to a study published online in the Journal ... [Published Chemotherapy Advisor - Aug 29 2014]
Entities: Hospice, Cancer, Admission
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

ACTINIUM PHARMACEUTICALS : Pharma :ceuticals Introduces Baylor Sammons Cancer Center as Clinical Trial Site

Actinium Pharmaceuticals reported the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A.According to a media release, the center joins several other clinical trial sites currently participating in the Actimab-A ... [Published 4 Traders - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Fate Therapeutics' (FATE) CEO Christian Weyer on Q2 2014 Results - Earnings Call Transcript

OperatorWelcome to Fate Therapeutics Second Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Fate’s website at fatetherapeutics.com. ... [Published Seeking Alpha - Aug 13 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Actinium Pharmaceuticals Adds Baylor Sammons Cancer Center as Clinical Trial Site

Actinium Pharmaceuticals reported the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. According to a media release, the center joins several other clinical trial sites currently participating in the Actimab-A ... [Published Individual.com - Aug 04 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Antifungal therapy may increase risk for pediatric mold infection

Treatment with antifungal therapy may be a risk factor for invasive mold infections, according to study findings in The Journal of the Pediatric Infectious Diseases Society .Rachel L. Wattier, MD, of the University of California San Francisco, and colleagues ... [Published Orthopedics Today - Aug 01 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium’s Actimab-A Clinical Trial

. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition ofM. Yair Levy, MD, Medical Director of Hematologic ... [Published Wall Street Select - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 1 reports

Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders

(GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. ( Nasdaq:FATE ), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) ... [Published Crawford Financial Planning - Jul 29 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Is a single positive blood culture for Enterococcus species representative of infection or contamination?

“Data on the clinical outcomes of patients with a single compared with multiple positive blood cultures for Enterococcus species is limited. We undertook a retrospective cohort study in adults with at least one positive blood culture for Enterococcus ... [Published IVTEAM - Jul 26 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Pre-Exercise Participation Cardiovascular Screening in a Heterogeneous Cohort of Adult Cancer Patients

Background. The purpose of this study was to investigate the extent of pre-exercise participation (“preparticipation”) health screening in a heterogeneous cohort of adult cancer patients.Methods. Patients (n = 413) with histologically confirmed solid ... [Published The Oncologist - Jul 25 2014]
Entities: Cohort, Risk, Screening, Cancer, ACSM
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Lymphoma Research Foundation Announces New Scientific Advisory Board Members

The Lymphoma Research Foundation (LRF) has announced the election of six experts in the field of lymphoma research to its prestigious Scientific Advisory Board (SAB). Comprised of the world's leading lymphoma researchers and oncologists, the Scientific ... [Published Industrial Info Financials - Jul 24 2014]
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial

Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ... [Published Marketwire - Breaking News Releases - Jun 12 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Variants of humanized immunomodulatory monoclonal antibodies

The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the ... [Published PharmCast - Apr 15 2014]

Quotes

O'Connor, Nina R , et al. "Hospice Admissions for Cancer in the Final Days of Life: Independent Predictors and Implications for Quality Measures." Journal of Clinical Oncology . doi: 10.1200/JCO.2014.55.8817. August 25, 2
Kaushik J Dave , Ph D , President and CEO of the Company stated, "We are pleased to work with Baylor Charles A Sammons Cancer Center , which is one of the largest oncology centers in the nation treating over 55,000 cancer patients every year. The selection reflects its commitment and significant experience in conducting clinical trials to evaluate the newest strategies for cancer prevention, diagnosis and treatment."
...transformative therapeutic intervention," commented Christian Weyer, M D , M A S , President and Chief Executive Officer of Fate Therapeutics. "We believe pharmacologically-optimized HSC therapeutics, such as PROHEMA, hold significant promise for improving outcomes in patients with inherited metabolic and other rare genetic disorders. FDA clearance of the PROVIDE study marks an important step towards our goal of clinically evaluating this novel treatment paradigm in the non-malignant disease setting."
"The Lymphoma Research Foundation's Scientific Advisory Board is comprised of the preeminent lymphoma specialists in the world and we are thrilled to have these six prominent individuals lend their expertise and talents to our Scientific Advisory Board" said LRF Chief Executive Officer Elizabeth Thompson

More Content

All (13) | News (12) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Factors in Late Hospice Admission for Cancer Id... [Published Chemotherapy Advisor - Aug 29 2014]
ACTINIUM PHARMACEUTICALS : Pharma :ceuticals In... [Published 4 Traders - Aug 13 2014]
Fate Therapeutics' (FATE) CEO Christian Weyer o... [Published Seeking Alpha - Aug 13 2014]
Actinium Pharmaceuticals Adds Baylor Sammons Ca... [Published Individual.com - Aug 04 2014]
Antifungal therapy may increase risk for pediat... [Published Orthopedics Today - Aug 01 2014]
Baylor Sammons Cancer Center Joins as Clinical ... [Published Wall Street Select - Jul 30 2014]
Fate Therapeutics Announces FDA Clearance of IN... [Published Crawford Financial Planning - Jul 29 2014]
Is a single positive blood culture for Enteroco... [Published IVTEAM - Jul 26 2014]
Pre-Exercise Participation Cardiovascular Scree... [Published The Oncologist - Jul 25 2014]
Lymphoma Research Foundation Announces New Scie... [Published Industrial Info Financials - Jul 24 2014]
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
ImmunoGen Inc. Announces Favorable Initial Safe... [Published BioPortfolio - Dec 09 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.